Abstract: Disclosed herein are double-stranded polyribonucleotides comprising a sense strand with 24 to 30 nucleotides in length and an antisense strand with 24 to 30 nucleotides in length, wherein the sense strand and the antisense strand form a fully complementary region of at least 24 base pairs with a blunt end at the 5?-end of the sense strand and the 3?-end of the antisense strand; and wherein the first 24 ribonucleotides at 5?-end of the sense strand further have at least one 2?-flourine modification at a ribonucleotide at a position selected from the group consisting of position number 2, 4, 6, 9, 10, 16, 21, 22, and 24, and no 2?-flourine modification at a ribonucleotide at a position selected from the group consisting of position number 1, 3, 8, and 14, and/or wherein the last 24 ribonucleotides at 3?-end of the antisense strand further have at least one 2?-flourine modification at a ribonucleotide at a position selected from the group consisting of position number 5, and 13, and no 2?-flourine modification a

Abstract: The present invention belongs to the field of biotechnology and pharmaceuticals. The present inventors found a sequence motif for identifying potent RIG-I agonists. Accordingly, the present invention is directed to a method for producing RIG-I agonists, the RIG-I agonists produced by said methods, and uses of said RIG-I agonists, as defined in the claims.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention belongs to the field of biotechnology and pharmaceuticals. The present inventors found a sequence motif for identifying potent RIG-I agonists. Accordingly, the present invention is directed to a method for producing RIG-I agonists, the RIG-I agonists produced by said methods, and uses of said RIG-I agonists, as defined in the claims.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.

Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.